Home/Pipeline/NAT-1

NAT-1

Various Cancers

DiscoveryActive

Key Facts

Indication

Various Cancers

Phase

Discovery

Status

Active

Company

Aptorum Group

About Aptorum Group

Aptorum Group is a publicly traded biopharmaceutical company dedicated to discovering and developing innovative therapies for diseases with significant unmet needs. Its strategy involves utilizing its proprietary platforms, including the ALS-4 platform for anti-infectives and the orphan drug-focused platform, to build a diversified pipeline. The company is advancing multiple candidates through early clinical stages while exploring strategic partnerships to accelerate development.

View full company profile

Therapeutic Areas

Oncology Infectious Diseases Metabolic Disorders Gastrointestinal

Other Various Cancers Drugs

Drug	Company	Phase	Status
Retifanlimab	Eli Lilly	Phase 2/3	Active
Imfinzi (durvalumab)	AstraZeneca	Approved	Commercial
Lynparza (olaparib)	Merck	Commercial	Active
Oncology Portfolio	Pfizer	Phase 1-3	Multiple Active Programs
PD-1 Inhibitor	Akeso	Phase 2/3	Active
Mitoxantrone Liposome	CSPC Pharmaceutical Group Limited	Phase 3	Active
Biosimilar Bevacizumab	Cipla	Commercial	Active
Tazverik (tazemetostat)	Eisai	Commercial	Discontinuation announced
Oncology Generics	Aurobindo Pharma	Commercial	Active
Opdivo (nivolumab)	Ono Pharmaceutical	Approved	Commercial
Oncology APIs (e.g., Sorafenib, Lenalidomide)	Laurus Labs	Commercial/Filed	Active
Tumor Marker Portfolio (PSA, CA125, etc.)	H.U. Group Holdings	Commercial	Active